By Brazil Stock Guide – JBS N.V. (NYSE: JBS; B3: JBSS32) reported a R$3.5 billion net profit in the third quarter of 2025, a result lower than the R$4.2 billion earned in the same period of 2024, reflecting tighter margins in key protein markets. Yet the company’s top line moved in the opposite direction: net revenue grew 11%, rising from R$110.5 billion to R$123.1 billion, showing continued commercial traction despite global price and cost volatility.
Operating income also came in weaker year over year, totaling R$6.6 billion versus R$8.6 billion in the third quarter of 2024. Financial expenses increased and helped compress the bottom line. Still, the company advanced on capital-market visibility and funding diversification after completing its NYSE listing and corporate restructuring earlier in the year.
Year-to-date results show a stronger trend
While the quarter shows a decline, the broader picture is more favorable. Over the first nine months of 2025, net profit surged 26%, rising from R$8.0 billion to R$10.1 billion. Net revenue in the same period climbed from R$300.3 billion to R$356.2 billion, an increase of 19%, driven by higher volumes and better pricing across markets.
Operating income year-to-date was essentially stable, at R$18.06 billion compared with R$18.12 billion in 2024. The stability masks pressure in some segments but also reflects tighter expense control and better asset utilization across regions. Financial results also improved slightly, with net financial expenses narrowing from R$6.86 billion to R$5.47 billion, giving the company additional breathing room.
Debt extension versus short-term pressure
JBS reinforced its balance sheet in July by issuing R$18.6 billion (US$3.5 billion) in long-term bonds. The proceeds were used to repurchase shorter-maturity notes, easing near-term obligations. This contrasts with 2024, when the group relied more heavily on short-term refinancing and carried higher interest costs.
Strategic expansion also accelerated. The acquisition of 90% of Granjeros Campo 9 in Paraguay and the US$100 million agreement for a new plant in Ankeny, Iowa, mark a more assertive growth pace compared with the same period last year.
Cash reinforced despite heavier working capital
Operating cash flow reached R$5.3 billion year to date, compared with R$14.6 billion in the same period of 2024 — a sharp decline driven mainly by working-capital consumption. Inventory buildup and grain price dynamics absorbed cash in 2025, whereas 2024 benefited from inventory release and favorable payables cycles.
Dividend inflows, however, helped offset the difference. In the third quarter alone, JBS received R$2.3 billion from JBS S.A. and another R$1.1 billion in October. The company had no comparable transfers in last year’s period at this scale.
A cycle of transition
Comparisons show a company navigating two speeds. Quarterly profitability weakened versus 2024, pressured by cattle availability in the U.S., feed costs and uneven global demand. But the year-to-date numbers tell a different story, highlighting stronger revenue traction, higher cumulative profit and a clearer capital-structure strategy.
JBS closed September with R$235 billion in total assets, slightly below the R$251.9 billion at the end of 2024, reflecting the distribution of dividends, currency effects and restructuring flows. Equity stood at R$50.6 billion, nearly stable against the R$50.4 billion at year-end.
The next quarters will show whether the momentum seen in the year-to-date view can offset the quarterly volatility that remains characteristic of the protein cycle.
Leave a Reply